Cigna Co. (NYSE:CI – Get Rating) EVP Nicole S. Jones sold 12,070 shares of the company’s stock in a transaction that occurred on Monday, April 18th. The shares were sold at an average price of $259.03, for a total value of $3,126,492.10. Following the transaction, the executive vice president now directly owns 35,201 shares of the company’s stock, valued at $9,118,115.03. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of Cigna stock traded up $7.84 on Wednesday, reaching $268.87. 1,452,542 shares of the stock were exchanged, compared to its average volume of 1,678,823. The firm has a market cap of $85.60 billion, a PE ratio of 17.08, a P/E/G ratio of 1.04 and a beta of 0.86. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.70 and a current ratio of 0.70. The firm’s 50 day moving average is $239.84 and its 200-day moving average is $226.33. Cigna Co. has a one year low of $191.74 and a one year high of $272.81.
Cigna (NYSE:CI – Get Rating) last issued its earnings results on Thursday, February 3rd. The health services provider reported $4.77 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $4.68 by $0.09. Cigna had a net margin of 3.08% and a return on equity of 14.59%. The business had revenue of $45.69 billion for the quarter, compared to analyst estimates of $43.98 billion. During the same period in the prior year, the firm earned $3.51 earnings per share. Cigna’s revenue was up 9.5% on a year-over-year basis. On average, equities research analysts expect that Cigna Co. will post 22.5 EPS for the current fiscal year.
A number of equities analysts recently issued reports on CI shares. Deutsche Bank Aktiengesellschaft lowered Cigna from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $271.00 to $236.00 in a report on Friday, February 4th. Sanford C. Bernstein upped their target price on Cigna from $234.00 to $258.00 in a research report on Tuesday, January 11th. Mizuho upped their target price on Cigna from $245.00 to $266.00 and gave the stock a “buy” rating in a research report on Wednesday, March 2nd. Truist Financial upped their target price on Cigna from $275.00 to $290.00 in a research report on Thursday, April 7th. Finally, SVB Leerink upped their target price on Cigna from $224.00 to $245.00 and gave the stock a “market perform” rating in a research report on Tuesday, February 22nd. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, fourteen have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $261.35.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Missouri Trust & Investment Co bought a new stake in Cigna in the fourth quarter worth $28,000. Wagner Wealth Management LLC grew its holdings in Cigna by 144.4% in the fourth quarter. Wagner Wealth Management LLC now owns 132 shares of the health services provider’s stock worth $30,000 after purchasing an additional 78 shares during the period. McIlrath & Eck LLC grew its holdings in shares of Cigna by 375.0% during the fourth quarter. McIlrath & Eck LLC now owns 133 shares of the health services provider’s stock valued at $31,000 after buying an additional 105 shares during the last quarter. Vectors Research Management LLC bought a new position in Cigna during the fourth quarter valued at approximately $31,000. Finally, FSB Premier Wealth Management Inc. bought a new position in Cigna in the fourth quarter worth approximately $32,000. Hedge funds and other institutional investors own 86.39% of the company’s stock.
About Cigna (Get Rating)
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care delivery and management, and intelligence solutions to health plans, employers, government organizations, and health care providers.
- Get a free copy of the StockNews.com research report on Cigna (CI)
- Highly Valued Abbot Laboratories Could Move Lower
- Baker Hughes, Another Buy-The-Dip Opportunity In Oilfield Services
- Netflix (NASDAQ: NFLX) Falls Back to 2018 Levels
- Is Turning Point Therapeutics Stock at a Turning Point?
- Buy Haliburton On Post-Earnings Weakness
Receive News & Ratings for Cigna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cigna and related companies with MarketBeat.com's FREE daily email newsletter.